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Abstract
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate
cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they
were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to
investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In
addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a
serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV
with CFS, at least in the UK.
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Introduction
Hitherto, gammaretroviruses have never been found in human
populations In mice, for example, the murine leukemia viruses
(MLVs) which belong to this genus of retroviruses can be both
exogenous and endogenous. Classically, endogenous MLVs are
categorised on the basis of their envelope gene sequence and their
cognate receptor polymorphism into ecotropic (replicating only in
murine cells), xenotropic (replicating in multiple mammalian cells,
including human but not murine cells), polytropic and modified
polytropic (able to grow in murine and nonmurine cells) [1].
The discovery by microarray technology of a retrovirus in
human prostates that was most closely related in its sequence to
the xenotropic MLVs explains its designation as xenotropic
murine leukemia virus-related virus (XMRV) [2]. Several reports
have since confirmed the XMRV association with prostate cancer
in the US [3–5], but not in Europe with the exception of one study
in Germany study in which it was found in one patient and one
control [6–8]. One Mexican study described the identification of
XMRV sequences in one healthy control, but not in prostate
tumor [9].
Interest in XMRV heightened when a study from the
Whittemore Peterson Institute, published in Science by Lombardi
et al [10] identified XMRV in 67% of patients suffering from
chronic fatigue syndrome (CFS) and in 3.7% of healthy controls.
One [11] of the many independent studies that failed to find
XMRV in a variety of CFS patient cohorts [12–17] amplified
instead genetic sequences closely related to the polytropic MLVs.
We [12] among others failed to confirm the presence of XMRV in
CFS patients tested not only in Europe [13,14] and China [15] but
also in the US [16,17] where the original study was carried out. It
has been suggested that these negative results could have arisen
because of a failure to duplicate the experimental conditions
described in the original publication by Lombardi et al [10]. To
remove any element of doubt, we have repeated our genetic
analysis using the same oligonucleotide primer sets described in
[10] and, in addition, we have assayed sera taken from 130 of our
CFS patients and 30 normal healthy subjects (NHS) for antibodies
to the New Zealand Black (NZB) xenotropic virus and its envelope
protein, gp70, a virus that shares more than 94% overall
homology with XMRV.
Materials and Methods
Patient samples
All patients gave written informed consent for the use of their
DNA to test aetiological theories of CFS, and the study was
approved by the South London and Maudsley NHS Trust Ethics
Committee. The patient samples have been described in detail
previously [12]. Briefly, patients were recruited into our study
from consecutive referrals to the CFS clinic at King’s College
Hospital, London and constitute a well-characterised and
representative sample of routine clinic attenders. All patients had
undergone medical screening to exclude detectable organic illness,
including a minimum of physical examination, urinalysis, full
blood count, urea and electrolytes, thyroid function tests, liver
function tests, 9 a.m. cortisol and ESR. Patients were interviewed
using a semi-structured interview [18]; all included patients met
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with the Fukuda-specified exclusionary psychiatric disorders, or
somatisation disorder (as per DSM-IV), were not included. The
use of standardised scales revealed high levels of fatigue and
disability (see [12] and supplementary correspondence for further
details). Overall we are confident that the patients in this study are
typical of those seen in secondary care and/or CFS clinics around
the world [20].
PCR amplification of XMRV sequences
DNA extraction has been described previously [12]. Briefly,
DNA was extracted from whole blood collected in EDTA. As a
control for DNA integrity, a 124 nucleotide (nt) section of the
human beta-globin gene was amplified. Amplification of XMRV
gag sequences was carried out using primers, 419F and 1154R, and
of env sequences using primers, 5922F and 6273R [10].
Reactions were carried out in a volume of 25 ml which
contained 0.5 units TaqGold (Applied BioSystems, Warrington,
UK), 16TaqGold reaction buffer (Applied BioSystems), 1.5 mM
Mg++, 200 mM each dNTP, 2.5 pmol each primer to which 5 ml
DNA extract or control (see below) was added. The PCR
conditions were as follows; one cycle at 94uC for 8 minutes, 45
cycles at 94uC for 30 seconds, 55uC for 30 seconds 72uC for
1 minute and a final annealing cycle of 72uC for 7 minutes. A 5 ml
aliquot of the PCR product was applied to a 1% agarose gel,
stained with Ethidium Bromide and subjected to electrophoresis.
Each PCR included six no-template (water) controls and a positive
control, plasmid pXMRV, containing the full-length XMRV
isolate, vp62, for which we are grateful to R. Silverman.
Serology
Sera from 130 CFS patients and 30 normal healthy subjects
(NHS) as controls were assayed blind and in duplicate for antibody
responses to the xenotropic NZB retrovirus envelope protein, gp70
by two independent ELISAs, based on antibodies against the NZB
virus and the ecotropic Rauscher MLV. For the assays, a CNBr-
activated Sepharose 4B column coupled with gp70-enriched
serum glycoproteins was used to affinity-purify either goat anti-
NZB xenotropic virus antibodies, or goat anti-Rauscher MLV
gp70 antibodies, as previously described [21].
gp70 antigen capture ELISA
Microtiter plates were coated with 83A25 rat IgG2a anti-
retroviral gp70 mAb (10 mg/ml), which recognizes xenotropic,
polytropic, ecotropic and amphotropic murine leukemia viruses
[22]. Serum samples were diluted 1:100 in PBS containing 1%
Figure 1. PCR amplification for XMRV in CFS patients. (A) Amplification products from nested PCR using XMRV env primers are shown. The env
specific product which is 352 nt long was not amplified from CFS patients 37–48, as shown in lanes 1–12, but was amplified from the plasmid pXMRV,
lane 13. The no-template controls are shown in lanes 14–19 and the DNA marker in lane 20. (B) The gag specific product, 736 nt in length, was not
amplified from the same CFS patient DNA samples, lanes 1–12. The DNA marker is shown in lane 13, the plasmid pXMRV in lane 14 and the water
controls in lanes 15–20.
doi:10.1371/journal.pone.0017592.g001
XMRV and CFS
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was detected following a 5-hour incubation with affinity-purified
goat anti-Rauscher MLV gp70 or affinity-purified goat anti-NZB
xenotropic virus antibodies, labelled with alkaline phosphatase.
Results are expressed as absorbance values at 405 nm (A405). In
these assays, 2-fold serially diluted NZB virus, obtained from
ViroMed Biosafety Laboratories, Camden, NJ, was used as a
positive control.
XMRV antibody response
Serum IgG anti-XMRV responses were determined by ELISA.
Microtiter plates were coated with whole inactivated NZB
retrovirus (10 mg/ml), and incubated with 1:100 diluted serum
samples overnight at 4uC. The assay was developed following a
5 hour incubation with alkaline phosphatase-labelled goat anti-
human IgG antibody (Cappel Laboratories, Durham, NC). The
A405 values are shown. As there is no defined XMRV-positive
human antiserum available, we used 603, a murine anti-Xeno
gp70 monoclonal antibody [23] as a positive control.
Statistical analysis
Data were analysed by unpaired Student’s T test comparison of
absorbance values between CFS patients and NHS controls. The
ELISA cut-off was calculated as the mean + 3 standard deviations
from the A405 value of the NHS sera.
Results
We examined 48 of the previously described [12] 186 samples
by PCR using primers derived from the gag and env regions of the
XMRV genome previously published by Lombardi et al [10]. No
amplicons were observed in either reaction (Figures 1a and 1b).
Sera from 130 CFS patients and 30 NHS controls were assayed
by ELISA for antibodies to MLV Env protein and in an antigen
capture ELISA for the presence of MLV Env itself. Results are
shown in Figures 2 and 3.
For the antibody ELISA, NZB virus was coated onto microtiter
plates and patient sera incubated at a dilution of 1:100. The
reaction was detected by alkaline phosphatase-labelled polyclonal
goat anti-human IgG antibody. The A405 value obtained with BSA
as background was 0.071. The cut-off was at 0.289. No specific
serological reaction could be detected (p=0.336, Figure 2).
For the antigen capture ELISA, 83A25 rat IgG2a antibody
raised against murine leukaemia virus envelope protein and able to
recognise xenotropic, polytropic, ecotropic and amphotropic
MLV [22], was coated onto microtiter plates and the serum
added at a dilution of 1:100. On Western blots this antibody
recognised recombinant XMRV envelope protein, gp70, pro-
duced in 293 T cells (data not shown). To detect bound Env
protein, affinity-purified polyclonal antibodies, goat anti-Rauscher
MLV gp70 or goat anti-NZB xenotropic virus labelled with
alkaline phosphatase were employed. These antibodies had
demonstrated reactivity to NZB virus in experiments using 2-fold
serial dilutions (Figure 3a). When goat anti-Rauscher MLV gp70
antibody was used as an XMRV detection reagent on sera from
CFS patients and NHS (Figure 3b), the background A405 value
obtained with BSA was 0.161. The cut-off value was 0.296. Four
CFS samples and one NHS sample gave A405 values above the
cut-off range, but the reactivity was not significant (p=0.632).
When using goat anti-NZB xenotropic virus antibody, the A405
value of BSA was of 0.095. Twenty CFS sera were significantly
above the cut-off value of 0.222, p value of 0.017 (Figure 3c).
However, the reactivity was not demonstrated in both ELISAs
(Table 1). For example, the CFS sera 122 and 186, which
displayed the highest A405 values of 0.730 and 0.371, respectively,
in the goat anti-NZB virus antibody ELISA, had A405 values of
0.159 and 0.138 in the goat anti-Rauscher gp70 MLV ELISA, a
value below the BSA background of 0.161. Moreover, CFS sera
261 and 61, which showed the highest absorption of o.492 and
0.419 in the goat anti-Rauscher gp70 ELISA, gave values of 0.181
and 0.167 (both below the cut-off value of 0.222) in the anti-NZB
virus antibody ELISA.
Only sera 17 and 185 produced A405 values of 0.304 and 0.327,
slightly above the cut-off of 0.296 in the goat anti-Rauscher MLV
antibody ELISA. These sera also had a modest reaction of 0.299
and 0.278 in the goat anti-NZB virus antibody ELISA (cut-off
being 0.222). However, as other samples showed similar
absorbance values in this assay that did not significantly react in
the goat anti-Rauscher gp70 MLV ELISA, the reactions are
considered to be non-specific. Taken together, these experiments
suggest that neither XMRV nor a specific serological response
against this family of viruses was found in CFS patients.
Discussion
The connection between XMRV and CFS remains highly
controversial. The initial report by Lombardi et al [10] identified
XMRV in 67% of CFS patients and 3.7% of health control
subjects. Subsequent to this, using the same experimental protocol
an independent study by Lo et al. [11] detected four classes of
MLV-related gag sequences in 86.5% of CFS patients and blood
donors. In this study [11] it was suggested that MLV-related
sequences found in CFS cases vary to the extent that they may
have remained undetected by our original PCR primers which
targeted the leader gag region and the pol region of XMRV. We
have now used the primers described in the original paper [10]
which bind to the XMRV gag and env open reading frames. We
have again failed to detect XMRV or MLV-related sequences in
48 of our CFS patients, demonstrating that our failure to find
XMRV in CFS tissue is not a reflection of the primers used in the
amplification process. Indeed, the original primer sets have been
Figure 2. Antibody ELISA using sera from CFS patients and
normal health subjects (NHS). The absorbance A405 values for 130
sera from CFS patients and NHS are shown. For the antibody ELISA
whole NZB xenotropic virus was coated to the microtitre plate following
incubation with serum samples overnight. Antibodies were detected by
incubation with anti-human IgG antibodies labelled with alkaline
phosphatase. The solid lines represent the mean. The BSA background
of 0.071 is represented by the dotted line.
doi:10.1371/journal.pone.0017592.g002
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sequences in CFS patient samples [14,16,17].
We have extended our study to investigate any possible
serological response to XMRV in our CFS patients, since there
appears to be a mis-match between PCR data and serology
[10,24]. In the absence of a specific XMRV serological assay, we
made use of an ELISA in which Goat anti-Rauscher MLV gp70
and goat anti-NZB xenotropic virus antibodies were employed to
detect gp70 Env protein in sera of CFS patients. In control
experiments these antibodies clearly recognised recombinant
XMRV gp70 Env expressed on dog thymus D17 cells (data not
shown). Both assays highlighted samples with A405 values above
the cut-off, however, for the goat anti-Rauscher MLV gp70
ELISA, this result was not significant. Using the goat anti-NZB
xenotropic virus ELISA, twenty sera were above the cut-off, but
most of these sera cluster outside the linear range with low
absorbance values at the limit of detection of the assay as indicated
by the flat curve b in Figure 3a. Considering further the fact that
these sera did not behave consistently in both ELISAs, we believe
that no specific serological reactions could be detected in the sera
of the CFS patients.
Figure 3. Antigen-capture ELISA using sera from CFS patients and NHS. (A) Goat anti-Rauscher MLV gp70 (lane a) and goat anti-NZB
xenotropic virus (lane b) antibodies were tested for their reactivity against NZB xenotropic virus in 2-fold serial dilutions starting with 10 mg/ml. The
A405 values are given. For the antigen capture ELISA, xenotropic virus envelope was captured onto the microtitre plate using 83A25 rat monoclonal
antibody [22]. Detection was then carried out using goat anti-Rauscher antibodies or goat anti-NZB xenotropic MLV gp70 antibodies. (B) Results
using goat anti-Rauscher MLV gp70 antibodies. The solid lines represent the mean and the dotted line indicates the BSA background of 0.161. (C)
Results shown for goat anti-NZB xenotropic virus antibodies. The solid line represents the mean and dotted line indicates the BSA background of
0.095.
doi:10.1371/journal.pone.0017592.g003
Table 1. Absorbance values of CFS sera in the two antigen-
capture ELISAS used.
ELISA A405
CFS patient number a-Rauscher a-NZB
17 0.304 0.299
61 0.419 0.167
261 0.492 0.181
185 0.327 0.278
122 0.159 0.730
186 0.138 0.371
a-Rauscher, goat anti-Rauscher MLV antibody.
a-NZB, goat anti-NZB antibody.
The values are the mean of two independent experiments. a -Rauscher, goat
anti-Rauscher gp70 MLV antibody; a-NZB, goat anti-NZB virus antibody.
doi:10.1371/journal.pone.0017592.t001
XMRV and CFS
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Switzer et al in an ELISA using recombinant XMRV Env protein
[16]. In this case, one of 51 sera from CFS patients and one from
53 healthy controls were slightly above the cut-off, but both sera
were negative by further testing by immunofluorescence assays
and PCR. Groom et al [14] detected some neutralisation activity
against MLV particles, pseudotyped with XMRV Env. This
neutralisation activity was also present in healthy blood donors
and showed no correlation with CFS [14], nor could XMRV
specific sequences be detected by PCR in these samples.
It would not be inconceivable that our failure to replicate was
due to patient differences. Clinical details of patients in the original
study [10] remain sparse. By contrast, we provide evidence
confirming that our patients not only had CFS, but had
considerable disability, and were not contaminated by either
exclusionary psychiatric or medical diagnoses. While it is true that
there will always be some variation based on local referral
practices, differences in health care provision and so on, and while
it is also true that CFS remains a difficult and elusive construct,
even when international consensus criteria are applied, we doubt
that this could explain the full range of differences in prevalence of
XMRV published to date.
Our serological data are consistent with the idea that XMRV
may be present in the human population at some level [14,16].
However, this study confirms our previous report that a
connection of XMRV or MLV-related viruses with UK CFS
patients could not be substantiated.
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